Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Enobosarm-d4 is intended for use as an internal standard for the quantification of enobosarm by GC- or LC-MS. Enobosarm is a non-steroidal selective androgen receptor modulator (SARM; Ki = 0.0038 µM in a radioligand binding assay).1 It is a partial agonist of the androgen receptor (IC50 = 0.0364 µM in a transactivation assay) and inhibits the proliferation of 22Rv1, DU145, LNCaP, and VCaP prostate cancer cells (IC50s = 24.77, 44.55, 20.9, and 24.47 µM, respectively).2 Enobosarm (0.001 and 0.01 µM) inhibits lipogenesis in isolated rat adipocytes.3 It increases the weights of the prostate gland and seminal vesicles, markers of androgenic activity, and the levator ani muscle, a marker of anabolic activity, in castrated rats (ED50s = 0.12, 0.39, and 0.03 mg/day, respectively).1
WARNING This product is not for human or veterinary use.
1. The para substituent of S-
2. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. Eur. J. Med. Chem. 118, 230-243 (2016).
3. Effect of ostarine (enobosarm/GTX024), a selective androgen receptor modulator, on adipocyte metabolism in Wistar rats. J. Physiol. Pharmacol. 70(4), 525-533 (2019).